Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Amylyx Pharmaceuticals, Inc. (United States)
Homepage:
amylyx.com
Alternate names:
Amylyx,
Amylyx Pharmaceuticals,
Amylyx Pharmaceuticals, Inc.
ROR:
03hngf113
OpenAlex ID:
I4405267609
Works
26
Awards
1
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
2020
·
Sabrina Paganoni
, Eric A. Macklin
, et al.
·
New England Journal of Medicine
·
562
PDF
Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis
2020
·
Sabrina Paganoni
, Suzanne Hendrix
, et al.
·
Muscle & Nerve
·
192
PDF
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
2022
·
Sabrina Paganoni
, Suzanne Hendrix
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
75
PDF
Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes
2022
·
Sabrina Paganoni
, Claire Watkins
, et al.
·
Muscle & Nerve
·
50
PDF
Multidimensional analysis and therapeutic development using patient iPSC–derived disease models of Wolfram syndrome
2022
·
Fumihiko Urano
, Rie Asada Kitamura
, et al.
·
JCI Insight
·
34
PDF
Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts
2022
·
Jasmine A. Fels
, Jalia Dash
, et al.
·
Annals of Clinical and Translational Neurology
·
32
Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial
2023
·
Robert Bowser
, Jiyan An
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
24
PDF
Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls
2023
·
Sabrina Paganoni
, Melanie Quintana
, et al.
·
Annals of Clinical and Translational Neurology
·
21
PDF
Biological effects of sodium phenylbutyrate and taurursodiol in Alzheimer's disease
2024
·
Steven E. Arnold
, Suzanne Hendrix
, et al.
·
Alzheimer s & Dementia Translational Research & Clinical Interventions
·
12
PDF
Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States
2025
·
Narghes Calcagno
, Erica Scirocco
, et al.
·
European Journal of Neurology
·
10
Contributions of neurologists to diagnostic timelines of ALS and thinkALS as an early referral instrument for clinicians
2024
·
Kuldip D. Dave
, Björn Oskarsson
, et al.
·
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
·
6
PDF
Phase II trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome
2026
·
Fumihiko Urano
, Bess A. Marshall
, et al.
·
Journal of Clinical Investigation
·
4
PDF
Phosphorylated Tau at Threonine 181 Is Elevated in Amyotrophic Lateral Sclerosis Plasma
2026
·
Tiziana Petrozziello
, Evan Mizerak
, et al.
·
Muscle & Nerve
·
3
PDF
Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer’s Disease: Integrated Clinical Trials Experience (S11.005)
2022
·
Steven E. Arnold
, Sabrina Paganoni
, et al.
·
Neurology
·
2
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Post-Bariatric Hypoglycemia (LUCIDITY)
2025
·
Ryan Miller
, Marilyn Tan
, et al.
·
Metabolism
·
1
CO202 Effect of an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol on Long-Term Tracheostomy/Ventilation-Free Survival and Hospitalization in Amyotrophic Lateral Sclerosis: Final Results from Centaur
2023
·
J. Schafer
, S. Hendrix
, et al.
·
Value in Health
·
1
PDF
SUN-627 Reduction in Rate of Hypoglycemic Events with Avexitide in Post-Bariatric Hypoglycemia: Results from the Phase 2 and 2b Studies
2025
·
Colleen Craig
, Tracey McLaughlin
, et al.
·
Journal of the Endocrine Society
PDF
Clinician Education Initiatives for General Neurologists on ALS: Why It Is Needed and ThinkALS, a Possible Solution (P5-11.008)
2024
·
Suma Babu
, Jill Yersak
, et al.
·
Neurology
Protocole d’utilisation thérapeutique et de suivi dans le cadre d’une autorisation d’accès compassionnel (AAC) pour AMX0035 aux patients atteints de sclérose latérale amyotrophique (SLA) en France
2024
·
Marie Le Goff
, Aude-Marie Duchesne
, et al.
·
Revue Neurologique
EE51 Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations
2023
·
R. Sharma
, N. Davison
, et al.
·
Value in Health
PDF
Evaluating the Effect of Sodium Phenylbutyrate and Taurursodiol on Survival Outcomes in Amyotrophic Lateral Sclerosis Using a Propensity Score–Matched Cohort From the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database (S33.005)
2023
·
Sabrina Paganoni
, Melanie Quintana
, et al.
·
Neurology
Bénéfices à long terme en termes de survie globale, fonction et sécurité d’emploi avec une association à dose fixe de phénylbutyrate de sodium et d’ursodoxicoltaurine (AMX0035) dans la sclérose latérale amyotrophique
2023
·
Marko Kokic
, Sabrina Paganoni
·
Revue Neurologique
Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS (4550)
2021
·
Sabrina Paganoni
, Suzanne Hendrix
, et al.
·
Neurology
P4‐023: Clinical Trial Design for a Phase Ii, Randomized, Placebo‐controlled Trial of Amx0035 in Alzheimer's Disease
2019
·
Kent L. Leslie
, Justin Klee
, et al.
·
Alzheimer s & Dementia
P3‐037: Clinical Trial Design for a Phase Ii, Randomized, Placebo‐controlled Trial of Amx0035 in Alzheimer's Disease
2018
·
Kent L. Leslie
, Joshua Cohen
, et al.
·
Alzheimer s & Dementia
Show more works
View as search
Works count:
26
Citation count:
3,687
Year
Topic
Type
